Liver Allograft Provides Immunoprotection for the Cardiac Allograft in Combined Heart–Liver Transplantation

T. W. Wong, M. J. Gandhi, R. C. Daly, S. S. Kushwaha, Naveen Luke Pereira, C. B. Rosen, Mark D Stegall, J. K. Heimbach, Timucin Taner

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

When transplanted simultaneously, the liver allograft has been thought to have an immunoprotective role on other organs; however, detailed analyses in simultaneous heart–liver transplantation (SHLT) have not been done to date. We analyzed patient outcomes and incidence of immune-mediated injury in 22 consecutive SHLT versus 223 isolated heart transplantation (IHT) recipients between January 2004 and December 2013, by reviewing 3912 protocol- and indication-specific cardiac allograft biopsy specimens. Overall survival was similar (86.4%, 86.4%, and 69.1% for SHLT and 93.3%, 84.7%, and 70.0% for IHT at 1, 5, and 10 years; p = 0.83). Despite similar immunosuppression, the incidence of T cell–mediated rejection (TCMR) was lower in SHLT (31.8%) than in IHT (84.8%) (p < 0.0001). Although more SHLT patients had preexisting donor-specific HLA antibody (22.7% versus 8.1%; p = 0.04), the incidence of antibody-mediated rejection was not different in SHLT compared with IHT (4.5% versus 14.8%, p = 0.33). While the left ventricular ejection fraction was comparable in both groups at 5 years, the incidence and severity of cardiac allograft vasculopathy were reduced in the SHLT recipients (42.9% versus 66.8%, p = 0.03). Simultaneously transplanted liver allograft was associated with reduced risk of TCMR (odds ratio [OR] 0.003, 95% confidence interval [CI] 0–0.02; p < 0.0001), antibody-mediated rejection (OR 0.04, 95% CI 0–0.46; p = 0.004), and cardiac allograft vasculopathy (OR 0.26, 95% CI 0.07–0.84; p = 0.02), after adjusting for other risk factors. These data suggest that the incidence of alloimmune injury in the heart allograft is reduced in SHLT recipients.

Original languageEnglish (US)
Pages (from-to)3522-3531
Number of pages10
JournalAmerican Journal of Transplantation
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Allografts
Transplantation
Liver
Heart Transplantation
Incidence
Odds Ratio
Confidence Intervals
Antibodies
Heart Injuries
Stroke Volume
Immunosuppression
Tissue Donors
Biopsy
Survival
Wounds and Injuries

Keywords

  • clinical research/practice
  • graft survival
  • heart (allograft) function/dysfunction
  • heart transplantation/cardiology
  • immunobiology
  • liver allograft function/dysfunction
  • liver transplantation/hepatology
  • rejection
  • rejection: T cell mediated (TCMR)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Cite this

Liver Allograft Provides Immunoprotection for the Cardiac Allograft in Combined Heart–Liver Transplantation. / Wong, T. W.; Gandhi, M. J.; Daly, R. C.; Kushwaha, S. S.; Pereira, Naveen Luke; Rosen, C. B.; Stegall, Mark D; Heimbach, J. K.; Taner, Timucin.

In: American Journal of Transplantation, Vol. 16, No. 12, 01.12.2016, p. 3522-3531.

Research output: Contribution to journalArticle

Wong, T. W. ; Gandhi, M. J. ; Daly, R. C. ; Kushwaha, S. S. ; Pereira, Naveen Luke ; Rosen, C. B. ; Stegall, Mark D ; Heimbach, J. K. ; Taner, Timucin. / Liver Allograft Provides Immunoprotection for the Cardiac Allograft in Combined Heart–Liver Transplantation. In: American Journal of Transplantation. 2016 ; Vol. 16, No. 12. pp. 3522-3531.
@article{8c12a0cea567482f94b1cab0cc29ccb4,
title = "Liver Allograft Provides Immunoprotection for the Cardiac Allograft in Combined Heart–Liver Transplantation",
abstract = "When transplanted simultaneously, the liver allograft has been thought to have an immunoprotective role on other organs; however, detailed analyses in simultaneous heart–liver transplantation (SHLT) have not been done to date. We analyzed patient outcomes and incidence of immune-mediated injury in 22 consecutive SHLT versus 223 isolated heart transplantation (IHT) recipients between January 2004 and December 2013, by reviewing 3912 protocol- and indication-specific cardiac allograft biopsy specimens. Overall survival was similar (86.4{\%}, 86.4{\%}, and 69.1{\%} for SHLT and 93.3{\%}, 84.7{\%}, and 70.0{\%} for IHT at 1, 5, and 10 years; p = 0.83). Despite similar immunosuppression, the incidence of T cell–mediated rejection (TCMR) was lower in SHLT (31.8{\%}) than in IHT (84.8{\%}) (p < 0.0001). Although more SHLT patients had preexisting donor-specific HLA antibody (22.7{\%} versus 8.1{\%}; p = 0.04), the incidence of antibody-mediated rejection was not different in SHLT compared with IHT (4.5{\%} versus 14.8{\%}, p = 0.33). While the left ventricular ejection fraction was comparable in both groups at 5 years, the incidence and severity of cardiac allograft vasculopathy were reduced in the SHLT recipients (42.9{\%} versus 66.8{\%}, p = 0.03). Simultaneously transplanted liver allograft was associated with reduced risk of TCMR (odds ratio [OR] 0.003, 95{\%} confidence interval [CI] 0–0.02; p < 0.0001), antibody-mediated rejection (OR 0.04, 95{\%} CI 0–0.46; p = 0.004), and cardiac allograft vasculopathy (OR 0.26, 95{\%} CI 0.07–0.84; p = 0.02), after adjusting for other risk factors. These data suggest that the incidence of alloimmune injury in the heart allograft is reduced in SHLT recipients.",
keywords = "clinical research/practice, graft survival, heart (allograft) function/dysfunction, heart transplantation/cardiology, immunobiology, liver allograft function/dysfunction, liver transplantation/hepatology, rejection, rejection: T cell mediated (TCMR)",
author = "Wong, {T. W.} and Gandhi, {M. J.} and Daly, {R. C.} and Kushwaha, {S. S.} and Pereira, {Naveen Luke} and Rosen, {C. B.} and Stegall, {Mark D} and Heimbach, {J. K.} and Timucin Taner",
year = "2016",
month = "12",
day = "1",
doi = "10.1111/ajt.13870",
language = "English (US)",
volume = "16",
pages = "3522--3531",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Liver Allograft Provides Immunoprotection for the Cardiac Allograft in Combined Heart–Liver Transplantation

AU - Wong, T. W.

AU - Gandhi, M. J.

AU - Daly, R. C.

AU - Kushwaha, S. S.

AU - Pereira, Naveen Luke

AU - Rosen, C. B.

AU - Stegall, Mark D

AU - Heimbach, J. K.

AU - Taner, Timucin

PY - 2016/12/1

Y1 - 2016/12/1

N2 - When transplanted simultaneously, the liver allograft has been thought to have an immunoprotective role on other organs; however, detailed analyses in simultaneous heart–liver transplantation (SHLT) have not been done to date. We analyzed patient outcomes and incidence of immune-mediated injury in 22 consecutive SHLT versus 223 isolated heart transplantation (IHT) recipients between January 2004 and December 2013, by reviewing 3912 protocol- and indication-specific cardiac allograft biopsy specimens. Overall survival was similar (86.4%, 86.4%, and 69.1% for SHLT and 93.3%, 84.7%, and 70.0% for IHT at 1, 5, and 10 years; p = 0.83). Despite similar immunosuppression, the incidence of T cell–mediated rejection (TCMR) was lower in SHLT (31.8%) than in IHT (84.8%) (p < 0.0001). Although more SHLT patients had preexisting donor-specific HLA antibody (22.7% versus 8.1%; p = 0.04), the incidence of antibody-mediated rejection was not different in SHLT compared with IHT (4.5% versus 14.8%, p = 0.33). While the left ventricular ejection fraction was comparable in both groups at 5 years, the incidence and severity of cardiac allograft vasculopathy were reduced in the SHLT recipients (42.9% versus 66.8%, p = 0.03). Simultaneously transplanted liver allograft was associated with reduced risk of TCMR (odds ratio [OR] 0.003, 95% confidence interval [CI] 0–0.02; p < 0.0001), antibody-mediated rejection (OR 0.04, 95% CI 0–0.46; p = 0.004), and cardiac allograft vasculopathy (OR 0.26, 95% CI 0.07–0.84; p = 0.02), after adjusting for other risk factors. These data suggest that the incidence of alloimmune injury in the heart allograft is reduced in SHLT recipients.

AB - When transplanted simultaneously, the liver allograft has been thought to have an immunoprotective role on other organs; however, detailed analyses in simultaneous heart–liver transplantation (SHLT) have not been done to date. We analyzed patient outcomes and incidence of immune-mediated injury in 22 consecutive SHLT versus 223 isolated heart transplantation (IHT) recipients between January 2004 and December 2013, by reviewing 3912 protocol- and indication-specific cardiac allograft biopsy specimens. Overall survival was similar (86.4%, 86.4%, and 69.1% for SHLT and 93.3%, 84.7%, and 70.0% for IHT at 1, 5, and 10 years; p = 0.83). Despite similar immunosuppression, the incidence of T cell–mediated rejection (TCMR) was lower in SHLT (31.8%) than in IHT (84.8%) (p < 0.0001). Although more SHLT patients had preexisting donor-specific HLA antibody (22.7% versus 8.1%; p = 0.04), the incidence of antibody-mediated rejection was not different in SHLT compared with IHT (4.5% versus 14.8%, p = 0.33). While the left ventricular ejection fraction was comparable in both groups at 5 years, the incidence and severity of cardiac allograft vasculopathy were reduced in the SHLT recipients (42.9% versus 66.8%, p = 0.03). Simultaneously transplanted liver allograft was associated with reduced risk of TCMR (odds ratio [OR] 0.003, 95% confidence interval [CI] 0–0.02; p < 0.0001), antibody-mediated rejection (OR 0.04, 95% CI 0–0.46; p = 0.004), and cardiac allograft vasculopathy (OR 0.26, 95% CI 0.07–0.84; p = 0.02), after adjusting for other risk factors. These data suggest that the incidence of alloimmune injury in the heart allograft is reduced in SHLT recipients.

KW - clinical research/practice

KW - graft survival

KW - heart (allograft) function/dysfunction

KW - heart transplantation/cardiology

KW - immunobiology

KW - liver allograft function/dysfunction

KW - liver transplantation/hepatology

KW - rejection

KW - rejection: T cell mediated (TCMR)

UR - http://www.scopus.com/inward/record.url?scp=84992745453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992745453&partnerID=8YFLogxK

U2 - 10.1111/ajt.13870

DO - 10.1111/ajt.13870

M3 - Article

C2 - 27184686

AN - SCOPUS:84992745453

VL - 16

SP - 3522

EP - 3531

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 12

ER -